ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 18 Issue : 4 Year: 2017
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR [Anatol J Cardiol]
Anatol J Cardiol. 2016; 16(8): 595-600 | DOI: 10.5152/AnatolJCardiol.2015.6474  

The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR

Ahmet Çelik1, Servet İzci2, Mehmet Ali Kobat3, Ahmet Hakan Ateş4, Abdülkadir Çakmak5, Yasin Çakıllı6, Mehmet Birhan Yılmaz7, Mehdi Zoghi8
1Department of Cardiology, Faculty of Medicine, Mersin University, Mersin- Turkey
2Department of Cardiology, Koşuyolu Education and Research Hospital, İstanbul- Turkey
3Department of Cardiology, Faculty of Medicine, Fırat University, Elazığ- Turkey
4Department of Cardiology, Samsun Education and Research Hospital, Samsun- Turkey
5Department of Cardiology, Faculty of Medicine, Amasya University, Amasya- Turkey
6Department of Cardiology, Siyami Ersek Education and Research Hospital, İstanbul- Turkey
7Department of Cardiology, Faculty of Medicine, Cumhuriyet University, Sivas- Turkey
8Department of Cardiology, Faculty of Medicine, Ege University, İzmir- Turkey

Objective: The awareness, time in therapeutic range (TTR), and safety of warfarin therapy were investigated in the adult Turkish population.
Methods: This multicenter prospective study includes 4987 patients using warfarin and involved regular international normalized ratio (INR) monitoring between January 1, 2014 and December 31, 2014. TTR was calculated according to F.R. Roosendaal’s algorithm. Awareness was evaluated based on the patients’ knowledge of warfarin’s affect and food–drug interactions.
Results: The mean TTR of patients was 49.52±22.93%. The patients with hypertension (55.3%), coronary artery disease (23.2%), congestive heart failure (24.5%), or smoking habit (20.8%) had significantly lower TTR levels than the others. Of the total number of patients, 42.6% had a mechanical valve, 38.4% had non-valvular atrial fibrillation (AF), and 19% had other indications for warfarin. Patients with other indications had lower TTR levels than those with mechanical valve and non-valvular AF (p=0.018). Warfarin awareness decreased in higher age groups. The knowledge of warfarin’s food–drug interactions was 55%. People with higher warfarin awareness had higher TTR levels. Patients with ≤8 INR monitoring/year had lower TTR levels (46.4±25.3 vs. 51.1±21.3, respectively, p<0.001) and lower awareness (44.6% vs. 60.6%, p<0.001) than patients with ≥8 INR monitoring/year. In this study, 20.1% of the patients had a bleeding event (major bleeding 15.8%, minor bleeding 84.2%) within a year.
Conclusion: Both the mean TTR ratios and awareness of the Turkish population on warfarin therapy were found to be low. It was thought that low TTR levels of the Turkish population may be caused by the low awareness of warfarin, warfarin’s food–drug interactions, and high rates of concomitant diseases. (Anatol J Cardiol 2016; 16: 000-00)

Keywords: time in therapeutic range, warfarin, Turkish population


Ahmet Çelik, Servet İzci, Mehmet Ali Kobat, Ahmet Hakan Ateş, Abdülkadir Çakmak, Yasin Çakıllı, Mehmet Birhan Yılmaz, Mehdi Zoghi. The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. Anatol J Cardiol. 2016; 16(8): 595-600

Corresponding Author: Ahmet Çelik, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2016 Turkish Society of Cardiology